Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833683 | 1.00 | CYP2A6 (0.54) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL7940513 | 0.97 | CYP2A6 (0.58) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL15848131 | 0.91 | CYP2A6 (0.63) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL8199794 | 0.84 | TDP1 (0.71) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL8200325 | 0.84 | CYP2A6 (0.68) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL364434 | 0.84 | SIGMAR1 (0.48) | L3MBTL1 | |
| SCHEMBL27486131 | 0.83 | CYP2A6 (0.58) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL13098626 | 0.82 | HRH1 (0.72) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL12040598 | 0.82 | HRH1 (0.72) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL3157976 | 0.81 | CYP2A6 (0.49) | CYP2A6TDP1L3MBTL1HRH1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129070-A4 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
| EP-1129070-A1 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000027811-A1 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | CYP2A6 2302/4885TDP1 222/4885L3MBTL1 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.